{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T14:09:12Z","timestamp":1784038152820,"version":"3.55.0"},"reference-count":56,"publisher":"American Society of Hematology","issue":"13","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,7,14]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Chronic lymphocytic leukemia (CLL) progression and therapeutic resistance are driven in large part by protective signals from the tumor microenvironment (TME), which includes T-cell\u2013derived cytokines such as interleukin-4 (IL-4) that promote survival via signal transducer and activator of transcription (STAT) signaling and upregulation of antiapoptotic proteins such as the B-cell lymphoma 2 (BCL-2) family member myeloid cell leukemia 1 (MCL-1). Although the BCL-2 inhibitor venetoclax has demonstrated significant clinical efficacy, microenvironment-induced resistance, particularly by MCL-1 upregulation, remains a major limitation. Here, we identify the US Food and Drug Administration\u2013approved antipsychotic drug pimozide as a dual-function agent that induces lysosome membrane permeabilization, leading to apoptosis in CLL cells through increased reactive oxygen species production. In addition, pimozide inhibited STAT5 phosphorylation, reduced IL-4\u2013induced MCL-1 expression, and prevented IL-4\/CD40L\u2013mediated inhibition of apoptosis. Importantly, pimozide remains effective in inducing apoptosis in CLL cells from patients who have relapsed after therapy. Pimozide also synergizes with venetoclax to induce apoptosis in CLL cells even after IL-4\/CD40L signaling. This suggests that dual targeting of lysosomal function and STAT signaling represents a promising therapeutic approach to improve venetoclax efficacy and overcome TME-mediated drug resistance in CLL.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2025018362","type":"journal-article","created":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T19:31:42Z","timestamp":1778009502000},"page":"4595-4608","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":0,"title":["Dual action of pimozide through lysosome disruption and inhibition of STATs induces apoptosis in chronic lymphocytic leukemia (CLL)"],"prefix":"10.1182","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-9747-2022","authenticated-orcid":false,"given":"Madhumita S.","family":"Manivannan","sequence":"first","affiliation":[{"name":"1Department of Oncology, Faculty of Medicine & Dentistry, University of Alberta, Edmonton, AB, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-1218-8958","authenticated-orcid":false,"given":"Xiaoyan","family":"Yang","sequence":"additional","affiliation":[{"name":"1Department of Oncology, Faculty of Medicine & Dentistry, University of Alberta, Edmonton, AB, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-8965-3236","authenticated-orcid":false,"given":"Nirav","family":"Patel","sequence":"additional","affiliation":[{"name":"1Department of Oncology, Faculty of Medicine & Dentistry, University of Alberta, Edmonton, AB, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2570-339X","authenticated-orcid":false,"given":"Anthea","family":"Peters","sequence":"additional","affiliation":[{"name":"1Department of Oncology, Faculty of Medicine & Dentistry, University of Alberta, Edmonton, AB, Canada"},{"name":"2Cross Cancer Institute, Alberta Health Services, Edmonton, AB, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0119-732X","authenticated-orcid":false,"given":"Spencer B.","family":"Gibson","sequence":"additional","affiliation":[{"name":"1Department of Oncology, Faculty of Medicine & Dentistry, University of Alberta, Edmonton, AB, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2026,6,26]]},"reference":[{"issue":"25","key":"2026071409581767200_bib1","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1182\/blood-2017-09-806398","article-title":"iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL","volume":"131","author":"Hallek","year":"2018","journal-title":"Blood"},{"issue":"5","key":"2026071409581767200_bib2","doi-asserted-by":"crossref","first-page":"873","DOI":"10.3324\/haematol.2013.099796","article-title":"The prognostic impact of minimal residual disease in patients with chronic lymphocytic leukemia requiring first-line therapy","volume":"99","author":"Santacruz","year":"2014","journal-title":"Haematologica"},{"issue":"3","key":"2026071409581767200_bib3","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1053\/j.seminhematol.2023.12.004","article-title":"Role of the tumor microenvironment in CLL pathogenesis","volume":"61","author":"vom Stein","year":"2024","journal-title":"Semin Hematol"},{"issue":"9","key":"2026071409581767200_bib4","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.3324\/haematol.2020.268037","article-title":"Targeting the tumor microenvironment in chronic lymphocytic leukemia","volume":"106","author":"Svanberg","year":"2021","journal-title":"Haematologica"},{"issue":"6","key":"2026071409581767200_bib5","doi-asserted-by":"crossref","first-page":"2676","DOI":"10.4049\/jimmunol.168.6.2676","article-title":"Cross-linking surface Ig delays CD40 ligand- and IL-4-induced B cell Ig class switching and reveals evidence for independent regulation of B cell proliferation and differentiation","volume":"168","author":"Rush","year":"2002","journal-title":"J Immunol"},{"issue":"4","key":"2026071409581767200_bib6","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1002\/1521-4141(200104)31:4<1150::AID-IMMU1150>3.0.CO;2-V","article-title":"B cells activated via CD40 and IL-4 undergo a division burst but require continued stimulation to maintain division, survival and differentiation","volume":"31","author":"Rush","year":"2001","journal-title":"Eur J Immunol"},{"issue":"1","key":"2026071409581767200_bib7","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/sj.cr.7290065","article-title":"Costimulation of resting B lymphocytes alters the IL-4-activated IRS2 signaling pathway in a STAT6 independent manner: implications for cell survival and proliferation","volume":"11","author":"Zamorano","year":"2001","journal-title":"Cell Res"},{"issue":"3","key":"2026071409581767200_bib8","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1046\/j.1365-2141.1999.01219.x","article-title":"IL4 production and increased CD30 expression by a unique CD8+ T-cell subset in B-cell chronic lymphocytic leukaemia","volume":"104","author":"de Totero","year":"1999","journal-title":"Br J Haematol"},{"issue":"1","key":"2026071409581767200_bib9","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/cytob.21120","article-title":"Distinctive patterns of na\u00efve\/memory subset distribution and cytokine expression in CD4 T lymphocytes in ZAP-70 B-chronic lymphocytic patients","volume":"86","author":"Monserrat","year":"2014","journal-title":"Cytometry B Clin Cytom"},{"issue":"24","key":"2026071409581767200_bib10","doi-asserted-by":"crossref","first-page":"3015","DOI":"10.1182\/blood-2015-11-682906","article-title":"IL-4 enhances expression and function of surface IgM in CLL cells","volume":"127","author":"Aguilar-Hernandez","year":"2016","journal-title":"Blood"},{"issue":"10","key":"2026071409581767200_bib11","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1182\/blood.2020010029","article-title":"Exploring the pathways to chronic lymphocytic leukemia","volume":"138","author":"Stevenson","year":"2021","journal-title":"Blood"},{"issue":"6","key":"2026071409581767200_bib12","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1182\/blood-2016-03-707786","article-title":"Surface IgM expression and function are associated with clinical behavior, genetic abnormalities, and DNA methylation in CLL","volume":"128","author":"D\u2019Avola","year":"2016","journal-title":"Blood"},{"issue":"5","key":"2026071409581767200_bib13","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1182\/blood.V100.5.1795.h81702001795_1795_1801","article-title":"Protection of CLL B cells by a follicular dendritic cell line is dependent on induction of Mcl-1","volume":"100","author":"Pedersen","year":"2002","journal-title":"Blood"},{"issue":"4","key":"2026071409581767200_bib14","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1182\/blood-2014-03-559690","article-title":"MicroRNA-155 influences B-cell receptor signaling and associates with aggressive disease in chronic lymphocytic leukemia","volume":"124","author":"Cui","year":"2014","journal-title":"Blood"},{"key":"2026071409581767200_bib15","doi-asserted-by":"crossref","first-page":"1005659","DOI":"10.3389\/fonc.2022.1005659","article-title":"Mechanisms of venetoclax resistance and solutions","volume":"12","author":"Liu","year":"2022","journal-title":"Front Oncol"},{"issue":"24","key":"2026071409581767200_bib16","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1056\/NEJMoa1400029","article-title":"Resistance mechanisms for the Bruton\u2019s tyrosine kinase inhibitor ibrutinib","volume":"370","author":"Woyach","year":"2014","journal-title":"N Engl J Med"},{"key":"2026071409581767200_bib17","doi-asserted-by":"crossref","first-page":"1549792","DOI":"10.3389\/fonc.2025.1549792","article-title":"Lysosome targeted therapies in hematological malignancies","volume":"15","author":"Manivannan","year":"2025","journal-title":"Front Oncol"},{"issue":"1","key":"2026071409581767200_bib18","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1146\/annurev-cellbio-111315-125125","article-title":"The lysosome as a regulatory hub","volume":"32","author":"Perera","year":"2016","journal-title":"Annu Rev Cell Dev Biol"},{"issue":"12","key":"2026071409581767200_bib19","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1038\/s41573-019-0036-1","article-title":"Lysosomes as a therapeutic target","volume":"18","author":"Bonam","year":"2019","journal-title":"Nat Rev Drug Discov"},{"key":"2026071409581767200_bib20","doi-asserted-by":"crossref","first-page":"642494","DOI":"10.3389\/fcell.2021.642494","article-title":"Lysosomes and cancer progression: a malignant liaison","volume":"9","author":"Machado","year":"2021","journal-title":"Front Cell Dev Biol"},{"issue":"12","key":"2026071409581767200_bib21","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.3390\/cells13121041","article-title":"Lysosome-disrupting agents in combination with venetoclax increase apoptotic response in primary chronic lymphocytic leukemia (CLL) cells mediated by lysosomal Cathepsin D release and inhibition of autophagy","volume":"13","author":"Manivannan","year":"2024","journal-title":"Cells"},{"issue":"6","key":"2026071409581767200_bib22","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1038\/leu.2016.4","article-title":"Lysosomotropic agents selectively target chronic lymphocytic leukemia cells due to altered sphingolipid metabolism","volume":"30","author":"Dielschneider","year":"2016","journal-title":"Leukemia"},{"issue":"6036","key":"2026071409581767200_bib23","first-page":"1429","article-title":"TFEB links autophagy to lysosomal biogenesis","volume":"332","author":"Settembre","year":"2011","journal-title":"Science (1979)"},{"issue":"12","key":"2026071409581767200_bib24","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.3390\/cancers11121939","article-title":"Chronic lymphocytic leukemia the JAK2\/STAT3 pathway is constitutively activated and its inhibition leads to CLL cell death unaffected by the protective bone marrow microenvironment","volume":"11","author":"Severin","year":"2019","journal-title":"Cancers (Basel)"},{"issue":"1","key":"2026071409581767200_bib25","doi-asserted-by":"crossref","first-page":"240","DOI":"10.3390\/cancers12010240","article-title":"Pharmacological inhibition of oncogenic STAT3 and STAT5 signaling in hematopoietic cancers","volume":"12","author":"Brachet-Botineau","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"3","key":"2026071409581767200_bib26","first-page":"274","article-title":"STAT5 activation promotes progression and chemotherapy-resistance in early T-cell precursor acute lymphoblastic leukemia","volume":"142","author":"Tremblay","year":"2023","journal-title":"Blood"},{"issue":"10","key":"2026071409581767200_bib27","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1038\/s41419-018-1003-1","article-title":"Loperamide, pimozide, and STF-62247 trigger autophagy-dependent cell death in glioblastoma cells","volume":"9","author":"Zielke","year":"2018","journal-title":"Cell Death Dis"},{"issue":"9","key":"2026071409581767200_bib28","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.3390\/cells9092141","article-title":"Pimozide suppresses the growth of brain tumors by targeting STAT3-mediated autophagy","volume":"9","author":"Ranjan","year":"2020","journal-title":"Cells"},{"issue":"9","key":"2026071409581767200_bib29","doi-asserted-by":"crossref","first-page":"101706","DOI":"10.1016\/j.xcrm.2024.101706","article-title":"Combinatorial targeting of glutamine metabolism and lysosomal-based lipid metabolism effectively suppresses glioblastoma","volume":"5","author":"Zhong","year":"2024","journal-title":"Cell Rep Med"},{"issue":"12","key":"2026071409581767200_bib30","doi-asserted-by":"crossref","first-page":"3421","DOI":"10.1182\/blood-2009-11-255232","article-title":"The STAT5 inhibitor pimozide decreases survival of chronic myelogenous leukemia cells resistant to kinase inhibitors","volume":"117","author":"Nelson","year":"2011","journal-title":"Blood"},{"issue":"7-8","key":"2026071409581767200_bib31","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1177\/1947601912466555","article-title":"The STAT5 inhibitor pimozide displays efficacy in models of acute myelogenous leukemia driven by FLT3 mutations","volume":"3","author":"Nelson","year":"2012","journal-title":"Genes Cancer"},{"issue":"18","key":"2026071409581767200_bib32","doi-asserted-by":"crossref","first-page":"4557","DOI":"10.3390\/cancers13184557","article-title":"Targeting autophagy triggers apoptosis and complements the action of venetoclax in chronic lymphocytic leukemia cells","volume":"13","author":"Avsec","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"1","key":"2026071409581767200_bib33","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1038\/s41467-025-56931-6","article-title":"Lysosomal NKG7 restrains mTORC1 activity to promote CD8+ T cell durability and tumor control","volume":"16","author":"Ham","year":"2025","journal-title":"Nat Commun"},{"issue":"1","key":"2026071409581767200_bib34","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1038\/srep01275","article-title":"Dysregulation of autophagy in chronic lymphocytic leukemia with the small-molecule Sirtuin inhibitor Tenovin-6","volume":"3","author":"MacCallum","year":"2013","journal-title":"Sci Rep"},{"issue":"4","key":"2026071409581767200_bib35","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.febslet.2010.12.043","article-title":"Lysosomal membrane permeabilization causes oxidative stress and ferritin induction in macrophages","volume":"585","author":"Ghosh","year":"2011","journal-title":"FEBS Lett"},{"key":"2026071409581767200_bib36","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.3389\/fonc.2020.01422","article-title":"Importance of crosstalk between chronic lymphocytic leukemia cells and the stromal microenvironment: direct contact, soluble factors, and extracellular vesicles","volume":"10","author":"Dubois","year":"2020","journal-title":"Front Oncol"},{"issue":"3","key":"2026071409581767200_bib37","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.bbamcr.2015.08.003","article-title":"The role of microenvironment and immunity in drug response in leukemia","volume":"1863","author":"Bakker","year":"2016","journal-title":"Biochim Biophys Acta"},{"issue":"1","key":"2026071409581767200_bib38","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1182\/bloodadvances.2020003423","article-title":"Overcoming resistance to targeted therapies in chronic lymphocytic leukemia","volume":"5","author":"Sk\u00e5nland","year":"2021","journal-title":"Blood Adv"},{"key":"2026071409581767200_bib39","doi-asserted-by":"crossref","first-page":"562196","DOI":"10.3389\/fonc.2020.562196","article-title":"Psychotropic drugs show anticancer activity by disrupting mitochondrial and lysosomal function","volume":"10","author":"Varalda","year":"2020","journal-title":"Front Oncol"},{"key":"2026071409581767200_bib40","doi-asserted-by":"crossref","first-page":"697950","DOI":"10.3389\/fonc.2021.697950","article-title":"STAT5a confers doxorubicin resistance to breast cancer by regulating ABCB1","volume":"11","author":"Li","year":"2021","journal-title":"Front Oncol"},{"issue":"2","key":"2026071409581767200_bib41","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/s41419-020-2335-1","article-title":"Suppressing STAT5 signaling affects osteosarcoma growth and stemness","volume":"11","author":"Subramaniam","year":"2020","journal-title":"Cell Death Dis"},{"issue":"5","key":"2026071409581767200_bib42","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1084\/jem.176.5.1319","article-title":"Interleukin 4 protects chronic lymphocytic leukemic B cells from death by apoptosis and upregulates Bcl-2 expression","volume":"176","author":"Dancescu","year":"1992","journal-title":"J Exp Med"},{"issue":"18","key":"2026071409581767200_bib43","doi-asserted-by":"crossref","first-page":"4403","DOI":"10.1182\/blood-2008-08-173310","article-title":"Concurrent up-regulation of BCL-XL and BCL2A1 induces approximately 1000-fold resistance to ABT-737 in chronic lymphocytic leukemia","volume":"113","author":"Vogler","year":"2009","journal-title":"Blood"},{"issue":"7","key":"2026071409581767200_bib44","doi-asserted-by":"crossref","first-page":"e105","DOI":"10.3324\/haematol.2013.101543","article-title":"STAT3 mutations are present in aggressive B-cell lymphomas including a subset of diffuse large B-cell lymphomas with CD30 expression","volume":"99","author":"Ohgami","year":"2014","journal-title":"Haematologica"},{"issue":"6","key":"2026071409581767200_bib45","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1038\/s41375-025-02577-8","article-title":"Dual STAT3\/STAT5 inhibition as a novel treatment strategy in T-prolymphocytic leukemia","volume":"39","author":"Dechow","year":"2025","journal-title":"Leukemia"},{"key":"2026071409581767200_bib46","doi-asserted-by":"crossref","first-page":"118959","DOI":"10.1016\/j.biopha.2025.118959","article-title":"JAK-STAT pathway in hematological malignancies: achievements, challenges and future perspectives","volume":"195","author":"Pan","year":"2026","journal-title":"Biomed Pharmacother"},{"issue":"14","key":"2026071409581767200_bib47","doi-asserted-by":"crossref","first-page":"2852","DOI":"10.1182\/blood-2009-10-230060","article-title":"STAT3 is constitutively phosphorylated on serine 727 residues, binds DNA, and activates transcription in CLL cells","volume":"115","author":"Hazan-Halevy","year":"2010","journal-title":"Blood"},{"issue":"10","key":"2026071409581767200_bib48","doi-asserted-by":"crossref","first-page":"e1451","DOI":"10.1038\/cddis.2014.393","article-title":"Viability and stress protection of chronic lymphoid leukemia cells involves overactivation of mitochondrial phosphoSTAT3Ser727","volume":"5","author":"Capron","year":"2014","journal-title":"Cell Death Dis"},{"issue":"11","key":"2026071409581767200_bib49","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1158\/2159-8290.CD-17-0996","article-title":"Targeting the lysosome for cancer therapy","volume":"7","author":"Towers","year":"2017","journal-title":"Cancer Discov"},{"issue":"9","key":"2026071409581767200_bib50","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1038\/nrc1692","article-title":"The role of autophagy in cancer development and response to therapy","volume":"5","author":"Kondo","year":"2005","journal-title":"Nat Rev Cancer"},{"issue":"5","key":"2026071409581767200_bib51","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1042\/BST20140145","article-title":"Lysosomotropic agents: impact on lysosomal membrane permeabilization and cell death","volume":"42","author":"Villamil Giraldo","year":"2014","journal-title":"Biochem Soc Trans"},{"issue":"24","key":"2026071409581767200_bib52","doi-asserted-by":"crossref","first-page":"5034","DOI":"10.1182\/blood-2008-12-196055","article-title":"FLT3-ITD up-regulates MCL-1 to promote survival of stem cells in acute myeloid leukemia via FLT3-ITD\u2013specific STAT5 activation","volume":"114","author":"Yoshimoto","year":"2009","journal-title":"Blood"},{"issue":"7","key":"2026071409581767200_bib53","doi-asserted-by":"crossref","first-page":"3193","DOI":"10.3390\/ijms26073193","article-title":"Double strike in chronic lymphocytic leukemia\u2014the combination of BTK and BCL2 inhibitors in actual and future clinical practice","volume":"26","author":"Zygmunciak","year":"2025","journal-title":"Int J Mol Sci"},{"issue":"10","key":"2026071409581767200_bib54","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1038\/s43018-024-00814-0","article-title":"BRD-810 is a highly selective MCL1 inhibitor with optimized in vivo clearance and robust efficacy in solid and hematological tumor models","volume":"5","author":"Rauh","year":"2024","journal-title":"Nat Cancer"},{"key":"2026071409581767200_bib55","doi-asserted-by":"crossref","first-page":"100672","DOI":"10.1016\/j.blre.2020.100672","article-title":"Targeting MCL-1 in hematologic malignancies: rationale and progress","volume":"44","author":"Wei","year":"2020","journal-title":"Blood Rev"},{"issue":"4","key":"2026071409581767200_bib56","doi-asserted-by":"crossref","first-page":"368504241296304","DOI":"10.1177\/00368504241296304","article-title":"Pimozide-loaded nanostructured lipid carriers: repurposing strategy against lung cancer","volume":"107","author":"AL-Haj","year":"2024","journal-title":"Sci Prog"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/13\/4595\/2530486\/blooda_adv-2025-018362-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/13\/4595\/2530486\/blooda_adv-2025-018362-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T13:58:28Z","timestamp":1784037508000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/13\/4595\/568180\/Dual-action-of-pimozide-through-lysosome"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,26]]},"references-count":56,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2026,7,14]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025018362","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,7,14]]},"published":{"date-parts":[[2026,6,26]]}}}